A solo show about cancer, comedy and a government-approved psilocybin trial is crossing the Atlantic for its European premiere at the Edinburgh Festival Fringe.

Patient 13, written and performed by American actor Gail Thomas, draws on her real-life experience of a cancer diagnosis and her participation in a clinical trial of psilocybin — the psychedelic compound found in so-called magic mushrooms. The show is billed as a dark comedy, running one hour, and has already clocked up 20 performances in the United States before making the journey to Scotland (WhatsOnStage).

Thomas is a Fringe first-timer. The 2026 engagement also marks the first time European audiences will see the piece. It is directed by Dan Oliverio and produced by Rhymes with Purple (Edinburgh Fringe programme).

The show runs at Zoo (Playground 2), a venue on the Grassmarket side of the Fringe campus, from 7 to 30 August. Performances are daily at 14:20, with dark days — no shows — on 17 and 25 August (WhatsOnStage). It is listed under the United States in the official Fringe programme, joining the annual wave of international work that floods Edinburgh each August.

For a show rooted in illness, the tone is deliberately unexpected. Thomas leans into comedy to carry a story about mortality and experimental medicine, a pairing that sits comfortably within the Fringe's tradition of solo work that refuses easy categorisation.

Psilocybin research has gathered pace in recent years, with clinical trials exploring the compound's potential in treating depression, anxiety and end-of-life distress. Thomas's trial was government-approved, placing her personal story inside a broader scientific moment.

The Edinburgh Festival Fringe, the world's largest arts festival, runs throughout August across hundreds of venues. For three weeks, the city hosts everything from established comedians and West End-bound dramas to first-time performers testing work in front of the most unpredictable audiences in the business. Thomas and Patient 13 step into that fray with a show already road-tested in America but brand-new to anyone this side of the Atlantic.